- Brand name:
- Pharmaceutical Company:
- Condition/Indication: Type 2 diabetes mellitus (T2DM)
- Meeting Date: November 2022
- Public Summary Document (PSD) August 2022 PBAC Out-of-Session - (PDF 330KB)
- Public Summary Document (PSD) August 2022 PBAC Out-of-Session - (Word 36KB)
Semaglutide – November 2022
Semaglutide: Solution for injection 2 mg in 1.5 mL pre-filled pen (s19A), Solution for injection 4 mg in 3 mL pre-filled pen (s19A); Ozempic® (UK)
Last updated
8 July 2025